Fig. 3From: Caregiver experiences and observations of intrathecal idursulfase-IT treatment in a phase 2/3 trial in pediatric patients with neuronopathic mucopolysaccharidosis IICaregiver-reported pre-trial impact of MPS II, with a prevalence of ≥ 15%. MPS II, Mucopolysaccharidosis IIBack to article page